SARS-CoV-2, the virus responsible for COVID-19, is often referred to as a flu-like virus due to its similar symptoms to influenza, including fever, cough, sore throat, muscle aches, and fatigue. This overlap in clinical features makes it challenging to differentiate between the two diseases based solely on symptoms. Both SARS-CoV-2 and influenza are transmitted through respiratory droplets and aerosols, reinforcing this classification. Numerous pathogens cause flu-like symptoms, including various influenza strains and other viruses like adenoviruses and rhinoviruses. Despite decades of vaccination efforts to combat these viruses, complete eradication remains elusive due to their rapid mutation rates and continual reintroduction from animal reservoirs. While vaccines have successfully reduced morbidity and mortality, flu-like viruses continue to circulate, necessitating ongoing immunization. Initially aimed at eradication, vaccination goals have shifted to controlling disease severity and protecting vulnerable populations, especially during the COVID-19 pandemic. The pervasive fear of infection resulted in a retreat from normal societal activities, triggering profound economic and social impacts. Consequently, public health strategies are now focused on minimizing the consequences of these viruses rather than aiming for their total elimination.